Back to resultsErythrocyte Complement Receptor 1 and Alzheimer Disease
Primary Purpose
Alzheimer Disease
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
CR1 impact
Sponsored by
About this trial
This is an interventional screening trial for Alzheimer Disease
Eligibility Criteria
Inclusion Criteria:
- caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects
Exclusion Criteria:
- diseases modifying CR1 physiology
Sites / Locations
- CHU de REIMS
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01565434
Brief Title
Erythrocyte Complement Receptor 1 and Alzheimer Disease
Study Type
Interventional
2. Study Status
Record Verification Date
March 2012
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
April 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CHU de Reims
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Other
Intervention Name(s)
CR1 impact
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects
Exclusion Criteria:
diseases modifying CR1 physiology
Facility Information:
Facility Name
CHU de REIMS
City
Reims
ZIP/Postal Code
51092
Country
France
12. IPD Sharing Statement
Learn more about this trial
Erythrocyte Complement Receptor 1 and Alzheimer Disease
We'll reach out to this number within 24 hrs